Medpace (MEDP) Projected to Post Quarterly Earnings on Wednesday

Medpace (NASDAQ:MEDP) is expected to be issuing its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect the company to announce earnings of $3.74 per share and revenue of $697.8220 million for the quarter. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 23, 2026 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.67 earnings per share. On average, analysts expect Medpace to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $528.44 on Tuesday. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 34.54, a PEG ratio of 2.50 and a beta of 1.39. The stock has a 50 day moving average price of $468.35 and a 200 day moving average price of $537.88. Medpace has a 52-week low of $250.05 and a 52-week high of $628.92.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Medpace

A number of hedge funds have recently bought and sold shares of MEDP. AQR Capital Management LLC lifted its holdings in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Medpace by 1,527.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 74,780 shares of the company’s stock valued at $38,449,000 after purchasing an additional 70,186 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of research reports. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Barclays upgraded Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target for the company in a report on Friday, March 6th. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.